SCHEMBL3450561

SCHEMBL3450561

C#CC(O)c1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
PTK2B Q14289 2/20 0.49
ADRA2C P18825 1/20 0.49
GFER P55789 1/20 0.49
KMT2A Q03164 1/20 0.49
ESR2 Q92731 1/20 0.49
CHKA P35790 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
SIRT6 Q8N6T7 1/20 0.42
HTR3A P46098 1/20 0.40
HDAC3 O15379 2/20 0.40
HDAC8 Q9BY41 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9533465 0.84 ALDH1A1 (0.41) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL29453319 0.81 HTR1A (0.43) ALDH1A1ADRA2CKMT2A
SCHEMBL7120656 0.81 ALDH1A1 (0.45) MAPTALDH1A1KDM4EGAAKMT2A
SCHEMBL23441685 0.80 MAPT (0.57) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL20354340 0.79 ALDH1A1 (0.55) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL12467619 0.75 ALDH1A1 (0.50) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL14095309 0.75 SIGMAR1 (0.57) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL27741267 0.75 NPC1 (0.51) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL101926 0.74 ALDH1A1 (0.64) MAPTALDH1A1KDM4EGAAPTK2B
SCHEMBL2370538 0.73 NPC1 (0.50) MAPTALDH1A1KDM4EGAAPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
EP-1537111-B1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2007-05-02 EP disclosed
EP-1537111-B1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2007-05-02 EP disclosed
US-20060142575-A1 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2006-06-29 US disclosed
EP-1537111-A1 HETEREOARYL NITRILE DERIVATIVES Novartis AG (CH) 2005-06-08 EP disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES CTSK, CTSS, CTSZ MAPT 3543/4885ALDH1A1 2393/4885KDM4E 1982/4885
US-20060142575-A1 Hetereoaryl nitrile derivatives CTSK, CTSZ, CTSE MAPT 3738/4885ALDH1A1 2727/4885KDM4E 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.